Omar Castaneda Puglianini, MD

Panelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.

Panelists discuss advice for patients with myeloma considering chimeric antigen receptor T-cell therapy, drawing from their experiences to guide patients through the decision-making process and expectations for the treatment journey.

Panelists discuss the protocol for long-term monitoring of patients who receive chimeric antigen receptor (CAR) T-cell therapy, focusing on relapse prevention and overall health, as well as the impact of CAR T-cell therapy on long-term management of patients with standard-risk disease, including additional steps to monitor disease progression and ongoing support in the months and years following treatment.

Panelists discuss how patients’ lives change after receiving chimeric antigen receptor (CAR) T-cell therapy, comparing the recovery process to previous lines of therapy, and how overall quality of life improves or changes following CAR T-cell treatment.

Panelists discuss how to monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients receiving this therapy and how to collaborate with the CAR T-cell therapy team during the treatment phase, emphasizing the most critical aspects of patient care at this stage.

Panelists discuss the key considerations in preparing patients for chimeric antigen receptor (CAR) T-cell therapy and how the treatment process differs when CAR T-cell therapy is used in earlier vs later stages of multiple myeloma.

Panelists discuss the chimeric antigen receptor (CAR) T-cell collection, manufacturing, and infusion process, highlighting how it differs from previous treatments, and share the challenges faced during CAR T-cell therapy, including managing adverse effects.

Panelists discuss the rationale for considering chimeric antigen receptor (CAR) T-cell therapy in standard-risk multiple myeloma and how health care providers help patients understand and prepare for the decision to pursue CAR T-cell treatment.

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.